ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
BörsenkürzelPRPH
Name des UnternehmensProphase Labs Inc
IPO-datumJan 16, 1984
CEOMr. Ted William Karkus
Anzahl der mitarbeiter96
WertpapierartOrdinary Share
GeschäftsjahresendeJan 16
Addresse711 Stewart Ave, Suite 200
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl11530
Telefon12153450919
Websitehttps://www.prophaselabs.com/
BörsenkürzelPRPH
IPO-datumJan 16, 1984
CEOMr. Ted William Karkus
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten